人乳寡糖(HMO) 市場規模、佔有率和成長分析（按類型、產品、應用、分銷管道和地區）- 2025-2032 年產業預測

2023 年人乳寡糖(HMO) 市場規模價值為 2.082 億美元，預計將從 2024 年的 2.2964 億美元成長到 2032 年的 5.0311 億美元，預測期內（2025-2032 年）的複合年成長率為 10.3%。

人乳寡糖(HMO) 市場作為嬰兒營養和健康的關鍵組成部分，正日益受到關注，並認知到其眾多的健康益處。母乳中天然存在的 HMO 可促進免疫系統成熟、胃腸道健康和認知發展。隨著研究的不斷深入，HMO 的潛在用途正在擴展到藥品、機能性食品和益生元補充劑。市場成長的主要驅動力包括人們對 HMO 健康益處的認知不斷提高，以及讓嬰兒奶粉更類似於母乳的動力。然而，挑戰依然存在，包括 HMO 生產的複雜性和高成本，以及監管和智慧財產權問題。儘管如此，正在進行的研究表明，HMO 不僅可以改善嬰兒營養，還可以解決整個生命週期中更廣泛的健康問題，這表明 HMO 在醫療保健和機能性食品領域有著變革性的未來。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

人乳寡糖(HMO) 市場規模（按類型和複合年成長率）（2025-2032 年）

• 市場概況
• 2'FL
• 3'FL
• 3'SL
• 6'SL

人乳寡糖(HMO) 市場規模（按產品和複合年成長率） (2025-2032)

• 市場概況
• 岩藻糖基乳糖
• 乳糖-N-四糖和乳糖-N-新四糖
• 唾液乳糖

人乳寡糖(HMO) 市場規模（按應用和複合年成長率） (2025-2032)

• 市場概況
• 嬰兒奶粉
• 機能性食品和飲料
• 營養補充品
• 人類和動物健康成分
• 其他

人乳寡糖(HMO) 市場規模（按分銷管道和複合年成長率） (2025-2032)

• 市場概況
• 大賣場和超級市場
• 藥局或藥房
• 量販店
• 百貨公司
• 單一品牌店
• 專賣店
• 網路銷售管道

人乳寡糖(HMO) 市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• DSM（Netherlands）
• BASF SE（Germany）
• DuPont（US）
• Nestle（Switzerland）
• Inbiose NV（Belgium）
• Gnubiotics Sciences SA（Switzerland）
• Abbott Laboratories（US）
• Royal FrieslandCampina NV（Netherlands）
• Elicityl SA（France）
• Dextra Laboratories（UK）
• Glycom A/S（Denmark）
• Glycosyn（US）
• Medolac Laboratories（US）
• Neolacta Lifesciences Pvt. Ltd.（India）
• Jennewein Biotechnologie GmbH（Germany）
• Lonza Specialty Ingredients（Switzerland）
• Kirin Holdings Company（Kyowa Hakko Bio）（Japan）
• ZuChem Inc.（US）

結論和建議

Human Milk Oligosaccharides (HMO) Market size was valued at USD 208.2 million in 2023 and is poised to grow from USD 229.64 million in 2024 to USD 503.11 million by 2032, growing at a CAGR of 10.3% during the forecast period (2025-2032).

The human milk oligosaccharides (HMO) market is gaining traction as a crucial component of infant nutrition and wellness, recognized for its myriad health benefits. Naturally occurring in breast milk, HMOs promote immune system maturation, gastrointestinal health, and cognitive development. As research advances, their potential applications are expanding into pharmaceuticals, functional foods, and prebiotic supplements. Key drivers of market growth include increasing awareness of HMOs' health benefits and the push to make infant formulas more akin to breast milk. However, challenges such as the complexity and high costs of HMO production, along with regulatory and intellectual property issues, remain significant. Nonetheless, ongoing research promises not only to enhance infant nutrition but also to address broader health concerns throughout the life cycle, indicating a transformative future for HMOs in healthcare and functional foods.

Top-down and bottom-up approaches were used to estimate and validate the size of the Human Milk Oligosaccharides (Hmo) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Human Milk Oligosaccharides (Hmo) Market Segments Analysis

Global Human Milk Oligosaccharides (HMO) Market is segmented by Type, Product, Application, Distribution channel and region. Based on Type, the market is segmented into 2'FL, 3'FL, 3'SL and 6'SL. Based on Product, the market is segmented into Fucosyllactose, Lnt & LNnt and Sialyllactose. Based on Application, the market is segmented into Infant formula, Functional food & beverages, Food supplements, Health ingredients for human and animal and Other. Based on Distribution channel, the market is segmented into Hypermarkets and supermarkets, Drug store or pharmacy, Mass merchandiser, Departmental stores, Mono-brand stores, Specialty stores and Online sales channel. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Human Milk Oligosaccharides (Hmo) Market

The rising recognition of the health benefits associated with human milk oligosaccharides (HMOs) serves as a significant catalyst for the market's expansion. As consumers become more informed about how HMOs contribute to enhanced immune function, cognitive growth, and gastrointestinal health, especially in infants, the demand for products fortified with these beneficial compounds has surged. This increased interest not only reflects parents' desire to provide optimal nutrition for their children but also highlights potential advantages for adults, further driving market growth. Consequently, the HMO market is experiencing a robust uptick, fueled by escalating awareness of their nutritional advantages.

Restraints in the Human Milk Oligosaccharides (Hmo) Market

The Human Milk Oligosaccharides (HMO) market faces significant restraints due to the intricate and challenging nature of HMO synthesis. The complexity of the processes involved complicates the scalability of HMO production, making it more difficult to achieve cost-effective manufacturing. The diverse array of HMO structures found in breast milk necessitates sophisticated and expensive techniques for replication, further hindering the industry's ability to produce these valuable components efficiently. As a result, these factors may limit the widespread availability and affordability of HMOs, ultimately impacting market growth and accessibility for potential consumers and manufacturers alike.

Market Trends of the Human Milk Oligosaccharides (Hmo) Market

The Human Milk Oligosaccharides (HMO) market is witnessing a significant trend towards expanding applications beyond traditional infant nutrition. While HMOs have primarily been associated with breastfeeding, their potential is now being explored in various sectors, including functional foods, dietary supplements, and pharmaceutical products. This shift is driven by growing scientific research showcasing the health benefits of HMOs, such as immune support and gut health improvement, for individuals across different age groups. Consequently, manufacturers are actively investing in developing innovative HMO-based solutions, positioning the market for substantial growth as consumer awareness of these benefits continues to rise.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Human Milk Oligosaccharides (HMO) Market Size by Type & CAGR (2025-2032)

• Market Overview
• 2'FL
• 3'FL
• 3'SL
• 6'SL

Global Human Milk Oligosaccharides (HMO) Market Size by Product & CAGR (2025-2032)

• Market Overview
• Fucosyllactose
• Lnt & LNnt
• Sialyllactose

Global Human Milk Oligosaccharides (HMO) Market Size by Application & CAGR (2025-2032)

• Market Overview
• Infant formula
• Functional food & beverages
• Food supplements
• Health ingredients for human and animal
• Other

Global Human Milk Oligosaccharides (HMO) Market Size by Distribution channel & CAGR (2025-2032)

• Market Overview
• Hypermarkets and supermarkets
• Drug store or pharmacy
• Mass merchandiser
• Departmental stores
• Mono-brand stores
• Specialty stores
• Online sales channel

Global Human Milk Oligosaccharides (HMO) Market Size & CAGR (2025-2032)

• North America (Type, Product, Application, Distribution channel)
  • US
  • Canada
• Europe (Type, Product, Application, Distribution channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Product, Application, Distribution channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Product, Application, Distribution channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Product, Application, Distribution channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• DSM (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BASF SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DuPont (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nestle (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inbiose NV (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gnubiotics Sciences S.A (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Royal FrieslandCampina N.V (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elicityl S.A (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dextra Laboratories (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glycom A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glycosyn (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medolac Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neolacta Lifesciences Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jennewein Biotechnologie GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Specialty Ingredients (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kirin Holdings Company (Kyowa Hakko Bio) (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ZuChem Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations